Self assembly Biological molecules are important lines to understand the molecular basis of complex metabolic events. The presence of cosolvent in aqueous solution during the self-assembly process can promote the formation of a metasable intermediary that is trapped in Kina. In nature, cosolvents categories called osmolytes can work to strengthen hydrogen bond tissue in such a way that the original conditions of certain proteins are preferred, thus modulating their functions and stability. However, identifying COSOLVENTs that act as osmolytes in biomimetic applications, such as self-assignment of soft materials, remain challenging.
This work examines the effects of ethanol (ETOH) and acetonitrile (ACN) as cosolven at the self-assignment of Amphiphilic Polypeptide PSAR30- (L-LEU-AIB) 6 (S30L12), which combines α-helical hydrophobic blocks, in aqueous solution. The result gives direct observation of the morphological behavior of S30L12 as a function of solvent composition. Morfological transitions are investigated using electron microscope transmissions, while peptide molecular packaging is assessed using circular blocked analysis and evaluating membrane fluidity.
In the mixture of Etoh / H2O, EtOH strengthens the water hydrogen bond tissue, thus limiting the hydrophobic hydration of the S30L12 assembly and increasing hydrophobic interactions between assemblies. Conversely, ACN forms its own nanoclusters in water and on the hydrophobic core of peptide assemblies to stabilize the edges exposed to bulk water and increase assembly kinetics. Fourier Transform Infrared Analysis (FT-IR) shows that EtOH and ACN can modify biomaterial self assembly in the same way as protective or denaturant osmolyte.
Poisonous polypeptide production as fusion inside the recit cavity
This system was developed for efficient biosynthetic production of painsty polypeptides. A polipeptide target produced blends into the T. thermophilus tassel polpeptide in such a way that it is served in the purai cavity near the substrate binding surface. Such presentations allow the relieve potential issues instability, toxicity or peptide hydrophobicity that blends. Thermostilical thermostabilities can be used to separate a one-step from the host cell protein by heating. The target of polypeptides can be released by special chemical care amino acids.
In this study, Groel was adapted for special methionine cleavage with cyanogen bromide with a total metionine residue replacement to facilitate further purification of the polipeptide target. The procedure is simple, strong, and easy to improve. The capacity of this system to produce polypeptides that is difficult to express is shown by production in the bacterial system from one of the most powerful antibacterial peptides polyphemusin I.
Adenilaty Adenilaty Polypeptide Adenilaty Cyclase: Neuroprotective Peptides that Promise in Stroke
Searching for effective and effective care for acute strokes continues to be a global priority due to high mortality and morbidity. Terapeutic treatment currently has limited effects, making searches for imperative new care. Polypeptides in the pituitary clasp (Pacip) are established cytoprotective neuropeptide participating in various physiological and pathological activities of nerves, such as neuron proliferation, differentiation, and migration, and neuroprotection. This is considered a promising treatment in many neurological diseases.
Thus, PACAP bears potential as a new therapeutic strategy for stroke treatment. Here, we provide an overview that is related to the current PACAP knowledge, its receptors, and the potential role of neuroprotective in stroke settings, as well as various neuroprotecting mechanisms involving ion homeostasis, excitoxicity, cell edema, and oxidative stress ,, and cell death, and the route of giving Pacap.
Polypeptide Amyloid Islet & Beta Amyloid Peptide Role In Alzheimer’s Disease: Two Triggers, One Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder that affects millions throughout the world. Because of the aging of the population, advertising events increase. Ad patients develop cognitive and dementia decreases, known features, requires permanent care. This raises the main socio-economic burden on the health care system because relatives and health workers are patients forced to overcome the increasing number of people affected. Despite the latest advances, the pathological mechanism of advertising is not fully understood.

However, it is clear that the amyloid beta (Aβ) peptide, which forms amyloid plaque in the brain of AD patients, plays a key role. Type 2 diabetes, the most common form of diabetes, affects hundreds of millions of people globally. The amyloid polypeptide (IAPP) islet is a hormone produced and released by insulin in the β-β pancreas, with a key role of diabetes, because it helps regulate glucose levels and control adiposity and pursuit. Likewise with Aβ, IAPP is very amyloidogenic, produces intracellular amyloid deposits that cause β cell dysfunction and death.
BCL6 siRNA |
20-abx908994 |
Abbexa |
|
|
|
BCL6 siRNA |
20-abx908995 |
Abbexa |
|
|
|
BCL6 Antibody |
1-CSB-PA005439 |
Cusabio |
|
|
|
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000 |
BCL6 Antibody |
1-CSB-PA908823 |
Cusabio |
|
|
|
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100 |
BCL6 Antibody |
1-CSB-PA040220 |
Cusabio |
|
|
|
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/10000 |
BCL6 Antibody |
1-CSB-PA040221 |
Cusabio |
|
|
|
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/40000 |
BCL6 Antibody |
6985-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: BCL6 Antibody: BCL6 was first identified as a proto-oncogene in diffuse large B cell lymphoma. BCL6, a transcriptional repressor, plays an important role in lymphomagenesis. It binds Stat recognition-like DNA elements and is required for affinity maturation of mature B cells in germinal centers and Th1/Th2 differentiation, a process that critically depends on BCL6-mediated transcriptional repression of p53. BCL6 is a pharmacological target for eradication of leukemia-initiating cells in chronic myeloid leukemia (CML). |
BCL6 Antibody |
6985-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: BCL6 Antibody: BCL6 was first identified as a proto-oncogene in diffuse large B cell lymphoma. BCL6, a transcriptional repressor, plays an important role in lymphomagenesis. It binds Stat recognition-like DNA elements and is required for affinity maturation of mature B cells in germinal centers and Th1/Th2 differentiation, a process that critically depends on BCL6-mediated transcriptional repression of p53. BCL6 is a pharmacological target for eradication of leukemia-initiating cells in chronic myeloid leukemia (CML). |
Bcl6 antibody |
70R-34469 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal Bcl6 antibody |
BCL6 antibody |
70R-11805 |
Fitzgerald |
100 ug |
EUR 552 |
Description: Rabbit polyclonal BCL6 antibody |
BCL6 Antibody |
37150-100ul |
SAB |
100ul |
EUR 302.4 |
BCL6 Antibody |
25523-100ul |
SAB |
100ul |
EUR 468 |
BCL6 antibody |
10R-1574 |
Fitzgerald |
100 ug |
EUR 614.4 |
Description: Mouse monoclonal BCL6 antibody |
Bcl6 Antibody |
V8063-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: The specificity of this monoclonal antibody to its intended target was validated by HuProtTM Array, containing more than 19,000, full-length human proteins. Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V8063-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: The specificity of this monoclonal antibody to its intended target was validated by HuProtTM Array, containing more than 19,000, full-length human proteins. Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V8063SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: The specificity of this monoclonal antibody to its intended target was validated by HuProtTM Array, containing more than 19,000, full-length human proteins. Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V8064-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V8064-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V8064SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3712-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3712-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3712SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3805-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3805-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3805SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V7340-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V7340-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V7340IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V7340SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V7350-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt] |
Bcl6 Antibody |
V7350-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt] |
Bcl6 Antibody |
V7350IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt] |
Bcl6 Antibody |
V7350SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt] |
Bcl6 Antibody |
V2840-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V2840-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V2840IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V2840SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3457-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3457-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3457SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3495-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3495-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3495SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3496-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3496-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3496SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
BCL6 Rabbit pAb |
A7173-100ul |
Abclonal |
100 ul |
EUR 369.6 |
BCL6 Rabbit pAb |
A7173-200ul |
Abclonal |
200 ul |
EUR 550.8 |
BCL6 Rabbit pAb |
A7173-20ul |
Abclonal |
20 ul |
EUR 219.6 |
BCL6 Rabbit pAb |
A7173-50ul |
Abclonal |
50 ul |
EUR 267.6 |
BCL6 Conjugated Antibody |
C37150 |
SAB |
100ul |
EUR 476.4 |
anti- BCL6 antibody |
FNab00849 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against BCL6 |
Bcl6 antibody (Ser333) |
70R-34468 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal Bcl6 antibody (Ser333) |
BCL6 (pS333) Antibody |
20-abx121849 |
Abbexa |
-
EUR 376.80
-
EUR 560.40
-
EUR 243.60
|
|
|
Anti-BCL6 Antibody |
A00142-1 |
BosterBio |
100ug/vial |
EUR 400.8 |
Polyclonal BCL6 Antibody |
APR06777G |
Leading Biology |
0.1 mg |
EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human BCL6 . This antibody is tested and proven to work in the following applications: |
Anti-Bcl6 Antibody |
PB9074 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-BCL6 antibody |
STJ29253 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: The protein encoded by this gene is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of STAT-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. This gene is found to be frequently translocated and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in the pathogenesis of DLCL. Alternatively spliced transcript variants encoding different protein isoforms have been found for this gene. |
Canine C-Peptide ELISA Kit |
DLR-C-Peptide-c-48T |
DL Develop |
48T |
EUR 632.4 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Canine C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Canine C-Peptide ELISA Kit |
DLR-C-Peptide-c-96T |
DL Develop |
96T |
EUR 825.6 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Canine C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Human C-Peptide ELISA Kit |
DLR-C-Peptide-Hu-48T |
DL Develop |
48T |
EUR 477.6 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Human C-Peptide ELISA Kit |
DLR-C-Peptide-Hu-96T |
DL Develop |
96T |
EUR 613.2 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Mouse C-Peptide ELISA Kit |
DLR-C-Peptide-Mu-48T |
DL Develop |
48T |
EUR 540 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Mouse C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Mouse C-Peptide ELISA Kit |
DLR-C-Peptide-Mu-96T |
DL Develop |
96T |
EUR 698.4 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Mouse C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Rat C-Peptide ELISA Kit |
DLR-C-Peptide-Ra-48T |
DL Develop |
48T |
EUR 560.4 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Rat C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Rat C-Peptide ELISA Kit |
DLR-C-Peptide-Ra-96T |
DL Develop |
96T |
EUR 726 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Rat C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Canine C-Peptide ELISA Kit |
RDR-C-Peptide-c-48Tests |
Reddot Biotech |
48 Tests |
EUR 668.4 |
Canine C-Peptide ELISA Kit |
RDR-C-Peptide-c-96Tests |
Reddot Biotech |
96 Tests |
EUR 928.8 |
Human C-Peptide ELISA Kit |
RDR-C-Peptide-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 484.8 |
Human C-Peptide ELISA Kit |
RDR-C-Peptide-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 667.2 |
Mouse C-Peptide ELISA Kit |
RDR-C-Peptide-Mu-48Tests |
Reddot Biotech |
48 Tests |
EUR 558 |
Mouse C-Peptide ELISA Kit |
RDR-C-Peptide-Mu-96Tests |
Reddot Biotech |
96 Tests |
EUR 771.6 |
Rat C-Peptide ELISA Kit |
RDR-C-Peptide-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 583.2 |
Rat C-Peptide ELISA Kit |
RDR-C-Peptide-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 806.4 |
Canine C-Peptide ELISA Kit |
RD-C-Peptide-c-48Tests |
Reddot Biotech |
48 Tests |
EUR 639.6 |
Canine C-Peptide ELISA Kit |
RD-C-Peptide-c-96Tests |
Reddot Biotech |
96 Tests |
EUR 888 |
Human C-Peptide ELISA Kit |
RD-C-Peptide-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 464.4 |
Human C-Peptide ELISA Kit |
RD-C-Peptide-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 638.4 |
Mouse C-Peptide ELISA Kit |
RD-C-Peptide-Mu-48Tests |
Reddot Biotech |
48 Tests |
EUR 535.2 |
Mouse C-Peptide ELISA Kit |
RD-C-Peptide-Mu-96Tests |
Reddot Biotech |
96 Tests |
EUR 738 |
Rat C-Peptide ELISA Kit |
RD-C-Peptide-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 558 |
Rat C-Peptide ELISA Kit |
RD-C-Peptide-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 771.6 |
Phospho-Bcl6 (Ser343) Antibody |
AF8244 |
Affbiotech |
200ul |
EUR 540 |
Phospho-Bcl6 (Ser333) Antibody |
AF3672 |
Affbiotech |
100ul |
EUR 540 |
Mouse BCL6 shRNA Plasmid |
20-abx969336 |
Abbexa |
|
|
|
Human BCL6 shRNA Plasmid |
20-abx950414 |
Abbexa |
|
|
|
BCL6 (Ab-333) Antibody |
CSB-PA935424-100ul |
Cusabio |
100ul |
EUR 379.2 |
|
Description: A polyclonal antibody against BCL6 (Ab-333). Recognizes BCL6 (Ab-333) from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
Phospho-BCL6 (S333) Antibody |
1-CSB-PA040219 |
Cusabio |
|
|
|
Description: A polyclonal antibody against Phospho-BCL6 (S333). Recognizes Phospho-BCL6 (S333) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/5000 |
Bcl6 Corepressor (BCOR) Antibody |
20-abx130647 |
Abbexa |
-
EUR 526.80
-
EUR 159.60
-
EUR 1479.60
-
EUR 710.40
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Bcl6 Corepressor (BCOR) Antibody |
20-abx130648 |
Abbexa |
-
EUR 510.00
-
EUR 159.60
-
EUR 1446.00
-
EUR 693.60
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Bcl6 Corepressor (BCOR) Antibody |
20-abx111212 |
Abbexa |
|
|
|
Bcl6 Corepressor (BCOR) Antibody |
20-abx212148 |
Abbexa |
|
|
|
Bcl6 Corepressor (BCOR) Antibody |
abx331577-100ul |
Abbexa |
100 ul |
EUR 510 |
|
Bcl6 Corepressor (BCOR) Antibody |
20-abx325854 |
Abbexa |
|
|
|
Bcl6 Corepressor (BCOR) Antibody |
20-abx213426 |
Abbexa |
|
|
|
Polyclonal BCL6 Antibody (Center) |
APR04907G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human BCL6 (Center). This antibody is tested and proven to work in the following applications: |
Recombinant Bcl6 Corepressor (BCOR) |
4-RPC327Hu01 |
Cloud-Clone |
-
EUR 603.84
-
EUR 285.60
-
EUR 1934.40
-
EUR 724.80
-
EUR 1329.60
-
EUR 480.00
-
EUR 4656.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Bcl6 Corepressor expressed in: E.coli |
Recombinant Bcl6 Corepressor (BCOR) |
4-RPC327Mu01 |
Cloud-Clone |
-
EUR 560.83
-
EUR 273.60
-
EUR 1773.12
-
EUR 671.04
-
EUR 1222.08
-
EUR 451.20
-
EUR 4252.80
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse Bcl6 Corepressor expressed in: E.coli |
Bcl6 Recombinant Protein (Mouse) |
RP119333 |
ABM |
100 ug |
Ask for price |
Bcl6 Recombinant Protein (Rat) |
RP192044 |
ABM |
100 ug |
Ask for price |
Bcl6 Recombinant Protein (Human) |
RP048364 |
ABM |
100 ug |
Ask for price |
BCL6 (Ab-333) Antibody |
CSB-PA935424- |
Cusabio |
each |
EUR 402 |
|
Description: A polyclonal antibody against BCL6 (Ab-333). Recognizes BCL6 (Ab-333) from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
bcl-6(BCL6/850) Antibody |
BNCA0850-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against bcl-6(BCL6/850), APC conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNCAP0850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNCAP0850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC610850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF660R conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC610850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF660R conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNUM0850-50 |
Biotium |
50uL |
EUR 474 |
Description: Primary antibody against bcl-6(BCL6/850), 1mg/mL |
bcl-6(BCL6/850) Antibody |
BNCR0850-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against bcl-6(BCL6/850), RPE conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNUB0850-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against bcl-6(BCL6/850), Concentration: 0.2mg/mL |
bcl-6(BCL6/850) Antibody |
BNUB0850-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against bcl-6(BCL6/850), Concentration: 0.2mg/mL |
bcl-6(BCL6/850) Antibody |
BNC430850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF543 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC430850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF543 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC400850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF640R conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC400850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF640R conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC880850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF488A conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC880850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF488A conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC800850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF680 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC800850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF680 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC810850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF680R conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC810850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF680R conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNCH0850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNCH0850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNCP0850-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against bcl-6(BCL6/850), PerCP conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC050850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF405M conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC050850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF405M conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC680850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF568 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC680850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF568 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC700850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF770 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC700850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF770 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNCB0850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), Biotin conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNCB0850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), Biotin conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC940850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF594 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC940850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF594 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC550850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF555 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC550850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF555 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC470850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF647 conjugate, Concentration: 0.1mg/mL |
bcl-6(BCL6/850) Antibody |
BNC470850-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF647 conjugate, Concentration: 0.1mg/mL |
Human Bcl6 Corepressor (BCOR) Protein |
20-abx168902 |
Abbexa |
-
EUR 844.80
-
EUR 343.20
-
EUR 2598.00
-
EUR 994.80
-
EUR 594.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Bcl6 Corepressor (BCOR) Protein |
20-abx168903 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2397.60
-
EUR 927.60
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
bcl-6(BCL6/850) Antibody |
BNC040850-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against bcl-6(BCL6/850), CF405S conjugate, Concentration: 0.1mg/mL |
Now it is clear that IAPP can also have a pathological role in AD, reducing cognitive function. IAPP harms blood-brain barriers, directly interacting and co-deposits with Aβ, promoting dementia associated with diabetes. IAPP can cause metabolic dysfunction in the brain, which leads to other diabetes advertisements. Thus, here we discuss the IAPP associations with diabetes, Aβ and dementia, in the context of what we specify “brain diabetes phenotype”. The hypothesis such approach helps establish a conceptual framework for IAPP-based drugs in the future against AD.